Toward a Tiered Model to Share Clinical Trial Data and Samples in Precision Oncology
暂无分享,去创建一个
Michiel Verlinden | Isabelle Huys | Stefanie Broes | Denis Lacombe | D. Lacombe | I. Huys | M. Verlinden | Stefanie Broes
[1] Daniel J Sargent,et al. Toward efficient trials in colorectal cancer: the ARCAD Clinical Trials Program. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Harlan M Krumholz,et al. Increasing value and reducing waste: addressing inaccessible research , 2014, The Lancet.
[3] Misha Angrist,et al. Personal genomes in progress: from the Human Genome Project to the Personal Genome Project , 2010, Dialogues in clinical neuroscience.
[4] Lee Murray,et al. The 100,000 Genomes Project , 2015 .
[5] Helen E. Parkinson,et al. The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog) , 2016, Nucleic Acids Res..
[6] G. Tortora,et al. EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.
[7] Sean Khozin,et al. Advantages of a Truly Open-Access Data-Sharing Model. , 2017, The New England journal of medicine.
[8] E. Zerhouni,et al. The role of public–private partnerships in addressing the biomedical innovation challenge , 2014, Nature Reviews Drug Discovery.
[9] A. Breckenridge,et al. Open Clinical Trial Data for All? A View from Regulators , 2012, PLoS medicine.
[10] Mark Barnes,et al. A Global, Neutral Platform for Sharing Trial Data. , 2016, The New England journal of medicine.
[11] Michael Morrison,et al. Dynamic consent: a patient interface for twenty-first century research networks , 2014, European Journal of Human Genetics.
[12] John A Spertus,et al. The double-edged sword of open access to research data. , 2012, Circulation. Cardiovascular quality and outcomes.
[13] Kay Dickersin,et al. Shaping the future of biomarker research in breast cancer to ensure clinical relevance , 2007, Nature Reviews Cancer.
[14] Arcadi Navarro,et al. The European Genome-phenome Archive of human data consented for biomedical research , 2015, Nature Genetics.
[15] Erik Schultes,et al. The FAIR Guiding Principles for scientific data management and stewardship , 2016, Scientific Data.
[16] C Sotiriou,et al. The AURORA initiative for metastatic breast cancer , 2014, British Journal of Cancer.
[17] Sabine Tejpar,et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.
[18] S. Gabriel,et al. Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.
[19] S. Beck,et al. Dynamic Consent: a potential solution to some of the challenges of modern biomedical research , 2017, BMC Medical Ethics.
[20] Gil Alterovitz,et al. All the World's a Stage: Facilitating Discovery Science and Improved Cancer Care through the Global Alliance for Genomics and Health. , 2015, Cancer discovery.
[21] Richard L Schilsky,et al. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] David Haussler,et al. Sharing Clinical and Genomic Data on Cancer - The Need for Global Solutions. , 2017, The New England journal of medicine.
[23] J. Tabernero,et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.
[24] Robert W. Corty,et al. The project data sphere initiative: accelerating cancer research by sharing data. , 2015, The oncologist.
[25] Balwir Matharoo-Ball,et al. Biobanking from the patient perspective , 2015, Research Involvement and Engagement.
[26] Daniel J Sargent,et al. The ARCAD clinical trials program: an update and invitation. , 2012, The oncologist.
[27] Ulrich Keilholz,et al. The combinatorial complexity of cancer precision medicine , 2014, Oncoscience.
[28] B. Fitzgerald. Guidance Regarding Methods for De-identification of Protected Health Information in Accordance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule , 2015 .
[29] Michael J Pencina,et al. Supporting open access to clinical trial data for researchers: The Duke Clinical Research Institute-Bristol-Myers Squibb Supporting Open Access to Researchers Initiative. , 2016, American heart journal.
[30] Charles C. Persinger,et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.
[31] Sabine Tejpar,et al. European perspective for effective cancer drug development , 2014, Nature Reviews Clinical Oncology.
[32] D A Flockhart,et al. Personal DNA Donation to Energize Genomic Medicine , 2014, Clinical pharmacology and therapeutics.
[33] Mark R. Trusheim,et al. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers , 2007, Nature Reviews Drug Discovery.
[34] Robert E. Hewitt,et al. Biobanking: the foundation of personalized medicine , 2011, Current opinion in oncology.
[35] Sean Khozin,et al. Regulatory watch: From big data to smart data: FDA's INFORMED initiative , 2017, Nature Reviews Drug Discovery.
[36] Kelly Edwards,et al. From patients to partners: participant-centric initiatives in biomedical research , 2012, Nature Reviews Genetics.
[37] International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome , 2001, Nature.
[38] Mark Barnes,et al. Preparing for responsible sharing of clinical trial data. , 2013, The New England journal of medicine.
[39] J. Scannell,et al. Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.
[40] Jedd D. Wolchok,et al. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy , 2016, Nature Reviews Clinical Oncology.
[41] Lesley Seymour,et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] K. Sirotkin,et al. The NCBI dbGaP database of genotypes and phenotypes , 2007, Nature Genetics.
[43] N. Cohen,et al. Open innovation networks between academia and industry: an imperative for breakthrough therapies , 2009, Nature Medicine.
[44] M. Parmar,et al. Sharing data from clinical trials: the rationale for a controlled access approach , 2015, Trials.
[45] Mike Clarke,et al. Good practice principles for sharing individual participant data from publicly funded clinical trials , 2015, Trials.
[46] Ira Shoulson,et al. Approaches and costs for sharing clinical research data. , 2014, JAMA.
[47] Ari B Friedman. Preparing for responsible sharing of clinical trial data. , 2014, The New England journal of medicine.
[48] Bart Van Looy,et al. Intellectual property policies in early-phase research in public–private partnerships , 2016, Nature Biotechnology.
[49] Gil McVean,et al. The 100,000 Genomes Project Protocol , 2017 .
[50] J Cuzick,et al. Improving decision making about clinical trial participation – a randomised controlled trial of a decision aid for women considering participation in the IBIS-II breast cancer prevention trial , 2014, British Journal of Cancer.
[51] Neil Savage. Getting Data Sharing Right to Help Fulfill the Promise of Cancer Genomics , 2017, Cell.
[52] Andrew V. Biankin,et al. The Challenges of Precision Oncology Drug Development and Implementation , 2015, Public Health Genomics.
[53] Michiel Verlinden,et al. Access to biobanks: harmonization across biobank initiatives. , 2014, Biopreservation and biobanking.
[54] Harlan M Krumholz,et al. The Yale Open Data Access (YODA) Project--A Mechanism for Data Sharing. , 2016, The New England journal of medicine.
[55] David P Carbone. Epidermal growth factor receptor overexpression: the importance of context. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] Mercè Crosas,et al. Data Authorship as an Incentive to Data Sharing. , 2017, The New England journal of medicine.
[57] Zhiwei Steven Wu,et al. Privacy-Preserving Generative Deep Neural Networks Support Clinical Data Sharing , 2017, bioRxiv.
[58] E. Hafen,et al. Health Data Cooperatives – Citizen Empowerment , 2014, Methods of Information in Medicine.
[59] Peter Høngaard Andersen,et al. Priorities for improving drug research, development and regulation , 2013, Nature Reviews Drug Discovery.
[60] Sigrid Sterckx,et al. Access to human tissues for research and product development , 2015, EMBO reports.
[61] Andreas Busch,et al. Industry–academia collaborations for biomarkers , 2015, Nature Reviews Drug Discovery.
[62] David J. Kerr,et al. Clinical cancer research: the past, present and the future , 2014, Nature Reviews Clinical Oncology.
[63] Rachel G Liao,et al. A federated ecosystem for sharing genomic, clinical data , 2016, Science.
[64] VerlindenMichiel,et al. Access to biobanks: harmonization across biobank initiatives. , 2014 .
[65] S. Hollingsworth,et al. Precision medicine in oncology drug development: a pharma perspective. , 2015, Drug discovery today.
[66] Frank Rockhold,et al. Data Sharing at a Crossroads. , 2016, The New England journal of medicine.
[67] Richard L Schilsky,et al. Cetuximab in the treatment of colorectal cancer. , 2004, Clinical advances in hematology & oncology : H&O.